Mycophenolate Mofetil

證據等級: L5

預測適應症: 10 個

Mycophenolate Mofetil: From Transplant Rejection Prophylaxis to HIV Infectious Disease

One-Sentence Summary

Mycophenolate mofetil (MMF) is a well-established immunosuppressant primarily used to prevent rejection after solid organ transplantation. The TxGNN model predicts it may also be effective for HIV Infectious Disease, with 10 clinical trials and 10 supporting publications currently reviewed, though most trials are small, terminated, withdrawn, or of unknown status.

Quick Overview

Item	Content
Original Indication	Prevention of organ transplant rejection (renal, cardiac, hepatic) — not captured in the evidence pack; based on established pharmacology of MMF
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.86%
Evidence Level	L2
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on established pharmacology, mycophenolate mofetil is a prodrug of mycophenolic acid (MPA), a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) type II. This enzyme is required for the de novo synthesis of guanine nucleotides — a pathway that activated T and B lymphocytes depend on heavily because they lack an efficient purine salvage route. This selective antiproliferative effect on lymphocytes is why MMF is used to suppress transplant rejection.

The hypothesized link to HIV infection rests on a different aspect of the same mechanism: chronic immune hyperactivation and clonal expansion of activated CD4+ T cells (the primary reservoir for HIV replication) drive disease progression. By depleting the guanine nucleotide pool in these activated cells, MMF could theoretically dampen immune-activation-driven viral replication and slow CD4+ T-cell depletion, independent of direct antiretroviral activity. Several groups also proposed a direct antiviral mechanism, since MPA-induced dGTP depletion can enhance the activity of guanosine-analogue reverse transcriptase inhibitors such as abacavir.

However, this rationale has been tested prospectively in several small Phase 1/2 studies over the past two decades, and the results are inconsistent: some trials show reduced HIV RNA or favorable immunological markers when MMF is added to abacavir-containing regimens, while the largest planned confirmatory studies (e.g., MAN2, NCT00120419) remain of unknown/unreported outcome, and a key adjunct trial (NCT00021489) was withdrawn before enrollment. The evidence therefore supports a plausible mechanism but not a demonstrated clinical benefit.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00120419	Phase 4	Unknown	90	MAN2 study — MMF for chronic immune hyperactivation in ART-naïve HIV-1 patients; assessed CD4+ decline, HIV-1 RNA, and disease progression; outcome not reported
NCT00038272	Phase 2	Completed	56	Compared DAPD alone vs DAPD + MMF in treatment-experienced patients; MMF was an adjunct, not the primary study drug
NCT01288131	Phase 3	Terminated	8	Cyclosporine + MMF vs cyclophosphamide + prednisolone for anti-r-HuEpo PRCA; not an HIV indication
NCT06869265	Phase 2	Recruiting	56	Conditioning regimen for haplo-HSCT in AML; MMF incidental (GVHD prophylaxis), unrelated to HIV
NCT00247494	Phase 4	Unknown	90	MAN2 substudy evaluating MMF's effect on cardiovascular surrogate markers in HIV-1 patients
NCT00021489	Phase 1/2	Withdrawn	0	Planned to test MMF + abacavir safety and antiretroviral activity in treatment-failure patients; withdrawn before any data collected
NCT02793544	Phase 2	Completed	80	MMF used for GVHD prophylaxis in HLA-mismatched unrelated donor BMT for hematologic malignancies; not HIV-related
NCT00112593	N/A	Completed	5	Allogeneic HSCT with post-transplant cyclosporine/MMF for mixed chimerism induction in HIV-1-positive patients
NCT01453192	Phase 3	Completed	27	Renal transplant follow-up in HIV-1 patients with ESRD; MMF used as standard post-transplant immunosuppression, not tested for antiviral effect
NCT00009009	Phase 2	Completed	10	Renal transplantation safety/efficacy in HIV-infected ESRD patients; MMF as standard immunosuppressant

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15213566	2004	Randomized pilot study	J Acquir Immune Defic Syndr	MMF during structured HAART interruption; assessed immune response and plasma/lymphatic viral load in 17 chronic HIV patients
15353978	2004	Clinical study	AIDS	HAART with or without MMF in treatment-naïve HIV-1 patients; examined effect on plasma HIV-1 RNA decay and latent reservoir
12352149	2002	Cohort	J Acquir Immune Defic Syndr	Adding MMF to abacavir-based ART associated with intracellular dGTP depletion and decreased plasma HIV-1 RNA in 5 heavily treated patients
16379601	2005	Cohort	AIDS Res Hum Retroviruses	No detrimental immunological effects observed with MMF + HAART in treatment-naïve acute/chronic HIV-1 patients
15871638	2005	Cohort/PK-PD	Clin Pharmacokinet	PK/PD of low-dose MMF combined with abacavir, efavirenz, and nelfinavir in HIV-infected patients
15355127	2004	Cohort/PK	Clin Pharmacokinet	Effect of MMF on antiretroviral drug pharmacokinetics and intracellular nucleoside triphosphate pools
11391161	2001	Pilot study	J Acquir Immune Defic Syndr	MMF as a component of salvage therapy in 7 patients with multidrug-resistant HIV-1; well tolerated, no significant decline in viral suppression noted
17885292	2007	Clinical study	AIDS	DAPD (amdoxovir) with or without MMF evaluated for safety, tolerability, and antiretroviral activity in drug-resistant HIV
17017956	2006	Review	Curr Top Med Chem	Overview of immunosuppressive drugs, including MMF, as potential adjuncts targeting immune activation in HIV disease
16515490	2006	Review	Curr Pharm Des	Review of "virostatic" agents, including MMF, as a strategy to target host factors sustaining HIV reservoirs

Norway Market Information

Currently not marketed in Norway — no authorization records are available in the evidence pack (total_licenses: 0).

Safety Considerations

TFDA-equivalent label warnings, contraindications, and drug interaction data are not currently available (flagged as a Blocking data gap, DG001 — download/parse required from the regulatory label source). Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: While the immune-activation hypothesis linking MMF to HIV disease control is mechanistically plausible and has been tested in several small studies, the trial evidence is inconsistent (multiple studies withdrawn, terminated, or of unknown/unreported outcome), no confirmatory Phase 2/3 RCT has established clinical benefit, and MMF is not currently marketed in Norway. Core safety data needed for a preliminary safety assessment (S1) is also missing.

To proceed, the following is needed:

TFDA/Norwegian label safety data — warnings, contraindications, DDI (DG001, currently Blocking)
Formal mechanism-of-action documentation from DrugBank (DG002)
Outcome data from the MAN2 study (NCT00120419/NCT00247494), currently listed as unknown status
A dedicated risk assessment for immunosuppression in an HIV-positive population (balancing antiviral hypothesis vs. risk of further immune impairment)
Norway/EU regulatory pathway assessment given the drug is not currently marketed in this indication or country
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.